Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP

Hassan Yousefnia, Samaneh Zolghadri, Hamid Reza Sadeghi, Mojdeh Naderi, Amir Reza Jalilian, Saeed Shanehsazzadeh

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

In this study, Lu-177-(4-{[(bis(phosphonomethyl))-carbamoyl] methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraaza-cyclododec-1-yl) acetic acid (Lu-177-BPAMD) was successfully prepared. The quality control, partition coefficient, hydroxyapatite binding assay and stability of the complex were determined. For better comparison, biodistribution patterns of Lu-177-BPAMD and Lu-177-EDTMP complexes were compared in same animal model. Lu-177-BPAMD was prepared with high radiochemical purity (>93 %) and specific activity of 534 GBq/mmol at the optimal conditions. Comparative study between Lu-177-BPAMD and Lu-177-EDTMP indicated higher bone uptake and lesser accumulation in the other organs for Lu-177-BPAMD. Lu-177-BPAMD can be considered as a promising agent for bone pain palliation in the near future.
Original languageEnglish
Pages (from-to)1243-1251
Number of pages9
JournalJournal of Radioanalytical and Nuclear Chemistry
Volume307
Issue number2
DOIs
Publication statusPublished - Feb 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP'. Together they form a unique fingerprint.

Cite this